Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
August 22, 2014, 04:43:33 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 635580
  • Total Topics: 48218
  • Online Today: 214
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 6
Guests: 160
Total: 166

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Clinical tests for medicines made from genitically modified plants  (Read 737 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Genetically modified tobacco plants to fight HIV?

U.K. regulators have, for the first time, approved a human clinical trial of a monoclonal antibody produced using genetically modified tobacco plants.

Monoclonal antibodies are made from identical immune cells that have been cloned from a unique parent cell to fulfill a specific role. The roots of this idea, which date back more than 100 years, helped German scientist Paul Ehrlich win a Nobel Prize in 1908 for work that ultimately resulted in an effective syphilis treatment.

But using tobacco plants that have been modified to stop the transmission of HIV is the culmination of a major 21st century project called Pharma-Planta, which was launched by a few dozen academic and industrial partners in 2004 with $17 million in funding from the European Union.

This initial trial in 11 participants will test the safety of the antibody, called P2G12, which is applied topically to the vaginal cavity and is thus specific to transmission to females. If it is proven to be safe, it will then be tested for effectiveness.

"This is a red-letter day for the field," Julian Ma, scientific coordinator for Pharma-Planta and professor of molecular immunology at St George's University of London, said in a statement. "The approval...is an acknowledgment that monoclonal antibodies can be made in plants to the same quality as those made using existing conventional production systems. That is something many people did not believe could be achieved."

Although the plants were grown in containment greenhouses by the Fraunhofer Institute for Molecular Biology and Applied Ecology in Germany, the consortium says one of the major advantages of using genetically modified plants to derive antibodies is that they can be grown in the very country that needs them, a boon for both the environment and local economies.

Such a boon could, of course, be a long way off. Fraunhofer custom-designed its processing plant to isolate and purify P2G12, a step that was both expensive and groundbreaking. In fact, the facility was the first of its kind to be granted a license to manufacture recombinant pharmaceutical products from plants in Europe.

Ultimately, the approval of clinical trials of P2G12 opens the door for trials of other plant-derived medicines that could treat a wide range of diseases.


http://www.fraunhofer.de/en/press/research-news/2010-2011/19/clinical-tests.jsp

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.